in line with FDA guidelines, the common primary therapeutic endpoint in this supplementary trial is a change in the value and severity of hot flashes in the 4th and 12th weeks in comparison to placebo.
The source of this page with content of products and services is from Internet,
which doesn't represent ECHEMI's opinion. If you have any queries, please write
to firstname.lastname@example.org. It will be replied within 5 days.
Moreover, if you find any instances of plagiarism from the page,
please send email to email@example.com with relevant evidence.